OraSure Technologies (NASDAQ:OSUR) Posts Earnings Results

OraSure Technologies (NASDAQ:OSUR) posted its quarterly earnings data on Wednesday. The medical instruments supplier reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03, FiscalAI reports. The business had revenue of $27.09 million during the quarter, compared to the consensus estimate of $28.96 million. OraSure Technologies had a negative net margin of 36.84% and a negative return on equity of 10.81%. OraSure Technologies updated its Q4 2025 guidance to EPS.

OraSure Technologies Price Performance

Shares of OraSure Technologies stock remained flat at $2.40 on Friday. The company had a trading volume of 474,417 shares, compared to its average volume of 701,087. OraSure Technologies has a 1 year low of $2.30 and a 1 year high of $4.36. The firm’s 50-day moving average is $3.09 and its two-hundred day moving average is $2.99. The firm has a market cap of $175.53 million, a P/E ratio of -3.58 and a beta of 0.54.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $3.00.

Institutional Trading of OraSure Technologies

A number of institutional investors and hedge funds have recently modified their holdings of OSUR. Amundi acquired a new position in OraSure Technologies in the 1st quarter valued at $47,000. AQR Capital Management LLC grew its holdings in shares of OraSure Technologies by 48.3% in the first quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock valued at $3,511,000 after purchasing an additional 339,493 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of OraSure Technologies by 32,595.9% in the first quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock worth $161,000 after acquiring an additional 47,590 shares in the last quarter. Empowered Funds LLC raised its position in OraSure Technologies by 7.2% in the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock valued at $1,366,000 after purchasing an additional 27,310 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in OraSure Technologies by 32.7% in the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 8,133 shares during the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.